PhRMA Continues Critique of ICER Drug Pricing Studies

The Pharmaceutical Research and manufacturers of America (PhRMA) have repeatedly spoken out against the cost-effectiveness studies published by the Institute for Clinical and Economic Review (ICER) and has recently publicized its own four pointed list of recommendations to ICER. Read more here. (Source: Joe Cantlupe, BioPharma DIVE, 9/29/16)

You might also be interested in:

PAI and BresMed Join Forces to Support Expanded Use of More… 07/22/2019
Biomarkers and Companion diagnostics: Payer Insights 09/26/2019
The Future of Personalised Medicine: The Role of Simulation… 01/25/2020
Research Operations for Secondary Use of Clinical Sites’ EMR 11/21/2019
Leveraging Technology to Reduce Costs in Clinical Trials 06/30/2019
The Global Use of Medicine in 2019 and Outlook to 2023 01/29/2019
The Growing Influence of the Institute of Clinical and… 11/21/2019